Patents Assigned to CRITICAL THERAPEUTICS
-
Publication number: 20110287023Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.Type: ApplicationFiled: March 18, 2011Publication date: November 24, 2011Applicants: Critical Therapeutics, Inc., MedImmune, LLCInventors: Herren Wu, Changshou Gao, Ling-Ling An, Peter Kiener, Su-Yau Mao, Anthony Coyle, Jane Tian, Theresa O'Keefe, Shixin Qin
-
Publication number: 20090202542Abstract: The present invention is drawn to fusion proteins comprising a Receptor for Advanced Glycation Endproducts (RAGE) and an immunoglobulin element. The invention also encompasses methods of treating a condition characterized by activation of an inflammatory cytokine cascade comprising administering such fusion proteins. The invention is also drawn to nucleic acids encoding the fusion proteins, as well as vectors and cells comprising such nucleic acids.Type: ApplicationFiled: November 19, 2008Publication date: August 13, 2009Applicant: Critical Therapeutics, Inc.Inventors: Theresa O'Keefe, Peter Luciano, Shixin Qin
-
Publication number: 20090169546Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn s disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.Type: ApplicationFiled: November 27, 2006Publication date: July 2, 2009Applicants: MEDIMMUNE, LLC, CRITICAL THERAPEUTICSInventors: Herren Wu, Changshou Gao, Ling-Ling An, Peter Kiener, Su-Yau Mao, Anthony Coyle, Jane Tian, Theresa O'Keefe, Shixin Qin
-
Patent number: 7470521Abstract: The present invention is drawn to fusion proteins comprising a Receptor for Advanced Glycation Endproducts (RAGE) and an immunoglobulin element. The invention also encompasses methods of treating a condition characterized by activation of an inflammatory cytokine cascade comprising administering such fusion proteins. The invention is also drawn to nucleic acids encoding the fusion proteins, as well as vectors and cells comprising such nucleic acids.Type: GrantFiled: July 20, 2005Date of Patent: December 30, 2008Assignee: Critical Therapeutics, Inc.Inventors: Theresa O'Keefe, Peter Luciano, Shixin Qin
-
Patent number: 7288250Abstract: In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.Type: GrantFiled: September 10, 2004Date of Patent: October 30, 2007Assignee: Critical Therapeutics, Inc.Inventors: Walter Newman, Shixin Qin, Theresa L. O'Keefe, Robert A. Obar
-
Publication number: 20050152903Abstract: In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.Type: ApplicationFiled: September 10, 2004Publication date: July 14, 2005Applicant: Critical Therapeutics, Inc.Inventors: Walter Newman, Shixin Qin, Theresa O'Keefe, Robert Obar
-
Publication number: 20040156851Abstract: Compositions and methods are disclosed for treating a condition characterized by activation of an inflammatory cytokine cascade in a patient. The compositions comprise an HMGB A box and an inhibitor of TNF biological activity, or an antibody that binds an HMGB polypeptide or biologically active fragment thereof and an inhibitor of TNF biological activity. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.Type: ApplicationFiled: November 20, 2003Publication date: August 12, 2004Applicant: Critical Therapeutics, Inc.Inventor: Walter Newman
-
Publication number: 20040141948Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise an HMGB A box, and an antibody preparation that specifically binds to an HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.Type: ApplicationFiled: November 20, 2003Publication date: July 22, 2004Applicant: Critical Therapeutics, Inc.Inventor: Theresa L. O'Keefe
-
Publication number: 20040068006Abstract: Disclosed is a method of treating acute renal failure in a subject. The method comprises the step of administering to the subject an effective amount of a composition comprising a 2-ketoalkanoic acid, a pharmaceutically acceptable salt of a 2-ketoalkanoic acid, an ester of a 2-ketoalkanoic acid, or an amide of a 2-ketoalkanoic acid. Preferably, the composition comprises an enolization agent and an alkyl aralkyl, alkoxyalkyl or carboxyalkyl ester of a 2-ketoalkanoic acid dissolved in a pharmaceutically acceptable vehicle.Type: ApplicationFiled: October 3, 2003Publication date: April 8, 2004Applicant: Critical Therapeutics, Inc.Inventors: Mitchell P. Fink, Howland Shaw Warren
-
Publication number: 20030232884Abstract: Disclosed is a pharmaceutical composition comprising an ester of an alpha-ketoalkanoic acid or an amide of an alpha-ketoalkanoic and lactic acid or a pharmaceutically acceptable salt of lactic acid dissolved in aqueous solution.Type: ApplicationFiled: April 17, 2003Publication date: December 18, 2003Applicant: Critical Therapeutics, Inc.Inventor: Mitchell P. Fink